Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017

Publisher Name :
Date: 13-Jun-2017
No. of pages: 42
Inquire Before Buying

Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape.

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat (steatorrhea), vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Exocrine Pancreatic Insufficiency - Overview
Exocrine Pancreatic Insufficiency - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Exocrine Pancreatic Insufficiency - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
Anthera Pharmaceuticals Inc
Celleron Therapeutics Ltd
Cilian AG
Laboratoires Mayoly Spindler SAS
Nordmark Arzneimittel GmbH & Co KG
Exocrine Pancreatic Insufficiency - Drug Profiles
burlulipase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cilase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CXD-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
liprotamase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-1819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Exocrine Pancreatic Insufficiency - Dormant Projects
Exocrine Pancreatic Insufficiency - Discontinued Products
Exocrine Pancreatic Insufficiency - Product Development Milestones
Featured News & Press Releases
May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial
Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura
Mar 19, 2015: Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
Jun 22, 2010: Protea Biosciences And Mayoly-­Spindler Announce Human Clinical Trial For New Biopharmaceutical.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H1 2017
Exocrine Pancreatic Insufficiency - Pipeline by Celleron Therapeutics Ltd, H1 2017
Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H1 2017
Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H1 2017
Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H1 2017
Exocrine Pancreatic Insufficiency - Dormant Projects, H1 2017
Exocrine Pancreatic Insufficiency - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global Varicose Vein Treatment Market Research Report 2017
    Published: 22-Jun-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Varicose Vein Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Varicose Vein Treatment in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Global Anti-inflammatory Therapeutics Market Research Report 2017
    Published: 21-Jun-2017        Price: US 2900 Onwards        Pages: 100
    In this report, the global Anti-inflammatory Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Anti-inflammatory Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America - Euro......
  • EMEA (Europe, Middle East and Africa) Brachytherapy Afterloaders, Brachytherapy Seeds Market Report 2017
    Published: 14-Jun-2017        Price: US 4000 Onwards        Pages: 107
    In this report, the EMEA Brachytherapy Afterloaders, Brachytherapy Seeds market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Brachytherapy Afterloaders, Brachytherapy Seeds for these regions, from 2012 to 2022 (forecast) -......
  • Global Anti-inflammatory Therapeutics Market 2017-2021
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 98
    Inflammation is a part of immune response triggered against harmful stimuli, foreign objects, damaged cells, irritants, and pathogens in the body. The drugs used to treat these symptoms are called anti-inflammatory drugs. It causes the elimination of the initial cause of cell injury, clearance of dead or necrotic cells, and damaged tissue from the site of the inflammatory process and initiates tissue repair. The analysts forecast global anti-inflammatory therapeutics market to grow at......
  • Global Substance Abuse Treatment Market 2017-2021
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 73
    Substance abuse is defined as an illicit use of alcohol, drugs, or cigarettes. They are potentially addictive in nature, difficult to treat, and have a negative impact on body and overall health. The major factors driving the market is the increase in substance usage and the number of associated deaths. It is also identified as a high economic burden. Substance abuse is one of the primary causes of death globally and a major economic burden. Substance abuse, along with addiction is associated......
  • United States Varicose Vein Treatment Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 13-Jun-2017        Price: US 4480 Onwards        Pages: 118
    There are several treatment options for Varicose Veins, wearing support stockings, Varicose Vein Treatment Devices; endogenous laser treatment, radiofrequency occlusion, surgery, and lasers and intense pulsed light. Mentioning medical devices for treating Varicose Veins, there is mainly Laser devices, Trivex and RFITT system. Scope of the Report: This report focuses on the Varicose Vein Treatment in United States market, to split the market based on manufacturers, states, ......
  • Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 35
    Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape. Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms......
  • Canavan Disease - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 25
    Canavan Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H1 2017, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape. Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene ......
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 40
    Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape. Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the defici......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs